PolyQ aggregation inhibitor C2-8

C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively) . It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.

Product Specifications

CAS Number

[300670-16-0]

Product Name Alternative

Polyglutamine Aggregation inhibitor III

UNSPSC

12352005

Hazard Statement

H319, H413

Target

Huntingtin

Type

Reference compound

Related Pathways

Neuronal Signaling

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/polyq-aggregation-inhibitor-c2-8.html

Purity

99.9

Smiles

O=C(NC1=CC=C(Br)C=C1)C2=CC=CC(S(=O)(NC3=CC=C(Br)C=C3)=O)=C2

Molecular Formula

C19H14Br2N2O3S

Molecular Weight

510.20

Precautions

H319, H413

References & Citations

[1]Zhang, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington’s disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 102 (3), 892-897 (2005) .